RPL17 and cancer: A key mechanism by which cancer limits the host immune response is by upregulating PD-1 ligands in the tumor microenvironment (TME) which mediate ligation of PD-1 on tumor-specific CD8+ T-cells, leading to the development of TEX cells that are incapable of generating anti-tumor responses14.